Nanobiotix SA (NBTX) News & EventsNBTXNanobiotix SA

Nanobiotix Appoints Arnd Christ as CFO

Nanobiotix announced the appointment of Arnd Christ as CFO and member of the company's executive board, effective October 1. Christ brings more than two decades of financial leadership in publicly listed biotechnology companies in Europe and the United States. He succeeds Bart Van Rhijn, who will step down as chief financial & business officer and member of the executive board after five years of service to the company.

Nanobiotix Releases Safety and Efficacy Data for JNJ-1900

Nanobiotix (NBTX) announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center evaluating radiotherapy-activated JNJ-1900 for patients with inoperable, locoregionally recurrent non-small cell lung cancer amenable to re-irradiation. The data were presented for the Study of Lung Cancer 2026 World Conference on Lung Cancer, taking place September 12-15 in Seoul, Republic of Korea. Results from the pooled dose-escalation and expansion phases showed that all 24 patients completed treatment with JNJ-1900 plus re-irradiation with no dose-limiting toxicities. Investigators reported no Grade 3 or higher adverse events related to JNJ-1900 or to the injection procedure. Grade 3 radiotherapy-related adverse events occurred in 33% of patients, and Grade 5 radiotherapy-related adverse events in 8%. The recommended Phase 2 dose was established at 33% of gross tumor volume. At a median follow-up of 12 months the one-year locoregional control rate was 79%. One-year local progression-free survival was 61%, and one-year overall survival was 70%. Investigators concluded that JNJ-1900 may permit clinically meaningful local control using a substantially lower re-irradiation dose. Enrollment in both the dose-escalation and expansion parts of the study is complete per protocol. Following the encouraging findings, additional patient enrollment in this study is planned. In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 with Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company.

Nanobiotix Shares Drop 9.0% to $39.28

Nanobiotix is down -9.0%, or -$3.88 to $39.28.